Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Documenti analoghi

• Young People With Type 2 Diabetes Are Under‐Represented in Randomized Clinical Trials
  di: Bowei Yu, et al.
  Pubblicazione: (2026)
• A 7‐year prospective analysis of sustained benefits of multicomponent risk assessment and data‐driven care in patients with type 2 diabetes: The Malaysian JADE Program
  di: Jia‐Xin Hoo, et al.
  Pubblicazione: (2025)
• Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
  di: Johnny T. K. Cheung, et al.
  Pubblicazione: (2024)
• Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting
  di: Michael A. Nauck, et al.
  Pubblicazione: (2026)
• The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
  di: Elias John Elenjickal, et al.
  Pubblicazione: (2026)